Rituximab Therapy for Rheumatoid Arthritis and Sjögren's Syndrome with Vasculitis

Medical Necessity and Standard of Care

The European League Against Rheumatism (EULAR) recommends rituximab for rheumatoid arthritis patients who have inadequate response to conventional DMARDs or TNF inhibitors, with a treatment plan of rituximab 1000mg IV every 6 months combined with hydroxychloroquine considered standard of care for patients with rheumatoid arthritis and Sjögren syndrome with vasculitis 1, 2
The American College of Rheumatology (ACR) guidelines include rituximab as an appropriate biologic option for patients with moderate to high disease activity, supporting the use of rituximab in combination with hydroxychloroquine for rheumatoid arthritis and Sjögren's syndrome with vasculitis 3

EULAR recommendations state that "the use of rituximab may be considered in patients with severe, refractory systemic disease, and the best indication is probably for vasculitis", supporting the use of rituximab for Sjögren's syndrome with vasculitis 4, 5
The combination of rituximab with hydroxychloroquine represents an evidence-based approach for patients with rheumatoid arthritis and systemic vasculitis, with hydroxychloroquine a standard DMARD for rheumatoid arthritis and Sjögren's syndrome 1, 4, 5

Regular monitoring of disease activity using validated measures is essential to confirm continued response to therapy, with the provider documenting a plan to evaluate the patient after each rituximab cycle 1, 2

The European League Against Rheumatism (EULAR) recommends rituximab as an appropriate treatment for patients with severe, refractory systemic manifestations of Sjögren's syndrome, particularly when associated with inflammatory arthritis, with a dosing regimen of 1000 mg IV at weeks 0 and 2, repeated every 6 months 6
Rituximab is considered an appropriate therapy for patients with Sjögren's syndrome with systemic manifestations, particularly inflammatory arthritis, as recommended by clinical guidelines 6
For patients with both Sjögren's syndrome and rheumatoid arthritis, rituximab represents a therapeutic option that addresses both conditions simultaneously, and is supported by clinical guidelines and evidence for use in Sjögren's syndrome with inflammatory arthritis 6